Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial

Eric G. Meissner; Mary McLaughlin; Lindsay Matthews; Ahmed M. Gharib; Bradford J. Wood; Elliot Levy; Ralph Sinkus; Kimmo Virtaneva; Dan Sturdevant; Craig Martens; Stephen F. Porcella; Zachary D. Goodman; Bittoo Kanwar; Robert P. Myers; Mani Subramanian; Colleen Hadigan; Henry Masur; David E. Kleiner; Theo Heller; Shyam Kottilil; Joseph A. Kovacs; Caryn G. Morse

doi:10.1111/liv.13177

Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial

Eric G. Meissner, Mary McLaughlin, Lindsay Matthews, Ahmed M. Gharib, Bradford J. Wood, Elliot Levy, Ralph Sinkus, Kimmo Virtaneva, Dan Sturdevant, Craig Martens, Stephen F. Porcella, Zachary D. Goodman, Bittoo Kanwar, Robert P. Myers, Mani Subramanian, Colleen Hadigan, Henry Masur, David E. Kleiner, Theo Heller, Shyam KottililJoseph A. Kovacs, Caryn G. Morse^*

^*Corresponding author for this work

Biomedical Engineering Department

Research output: Contribution to journal › Article › peer-review

83 Citations (Scopus)

Abstract

Drugs that reverse liver fibrosis are currently getting developed. Non-invasive quantification of the fibrosis degree is key to monitor therapy. This clinical trial for a novel drug was conducted at NIH. MR-Elastography was used as imaging biomarker to verify whether success of therapy can be monitored via biomechanics. MRE showed that the drug had no effect which was confirmed by histopathology. While for the drug company a deception, for MRE this was a success since it is more difficult to "see nothing when there is nothing". This paper convinced a major MRI constructor to translate our technology into a product.

Original language	English
Pages (from-to)	1783-1792
Number of pages	10
Journal	LIVER INTERNATIONAL
Volume	36
Issue number	12
Early online date	27 May 2016
DOIs	https://doi.org/10.1111/liv.13177
Publication status	Published - 1 Dec 2016

Keywords

hepatic venous pressure gradient
lysyl oxidases
magnetic resonance elastography
transforming growth factor beta-3

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/liv.13177

Cite this

Meissner, E. G., McLaughlin, M., Matthews, L., Gharib, A. M., Wood, B. J., Levy, E., Sinkus, R., Virtaneva, K., Sturdevant, D., Martens, C., Porcella, S. F., Goodman, Z. D., Kanwar, B., Myers, R. P., Subramanian, M., Hadigan, C., Masur, H., Kleiner, D. E., Heller, T., ... Morse, C. G. (2016). Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. LIVER INTERNATIONAL, 36(12), 1783-1792. https://doi.org/10.1111/liv.13177

@article{4df6146f91d043249e03b4c90ab2c9e4,

title = "Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial",

abstract = "Drugs that reverse liver fibrosis are currently getting developed. Non-invasive quantification of the fibrosis degree is key to monitor therapy. This clinical trial for a novel drug was conducted at NIH. MR-Elastography was used as imaging biomarker to verify whether success of therapy can be monitored via biomechanics. MRE showed that the drug had no effect which was confirmed by histopathology. While for the drug company a deception, for MRE this was a success since it is more difficult to {"}see nothing when there is nothing{"}. This paper convinced a major MRI constructor to translate our technology into a product.",

keywords = "hepatic venous pressure gradient, lysyl oxidases, magnetic resonance elastography, transforming growth factor beta-3",

author = "Meissner, {Eric G.} and Mary McLaughlin and Lindsay Matthews and Gharib, {Ahmed M.} and Wood, {Bradford J.} and Elliot Levy and Ralph Sinkus and Kimmo Virtaneva and Dan Sturdevant and Craig Martens and Porcella, {Stephen F.} and Goodman, {Zachary D.} and Bittoo Kanwar and Myers, {Robert P.} and Mani Subramanian and Colleen Hadigan and Henry Masur and Kleiner, {David E.} and Theo Heller and Shyam Kottilil and Kovacs, {Joseph A.} and Morse, {Caryn G.}",

year = "2016",

month = dec,

day = "1",

doi = "10.1111/liv.13177",

language = "English",

volume = "36",

pages = "1783--1792",

journal = "LIVER INTERNATIONAL",

issn = "1478-3223",

publisher = "Wiley-Blackwell",

number = "12",

}

Meissner, EG, McLaughlin, M, Matthews, L, Gharib, AM, Wood, BJ, Levy, E, Sinkus, R, Virtaneva, K, Sturdevant, D, Martens, C, Porcella, SF, Goodman, ZD, Kanwar, B, Myers, RP, Subramanian, M, Hadigan, C, Masur, H, Kleiner, DE, Heller, T, Kottilil, S, Kovacs, JA & Morse, CG 2016, 'Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial', LIVER INTERNATIONAL, vol. 36, no. 12, pp. 1783-1792. https://doi.org/10.1111/liv.13177

TY - JOUR

T1 - Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults

T2 - results of a 6-month open-label safety trial

AU - Meissner, Eric G.

AU - McLaughlin, Mary

AU - Matthews, Lindsay

AU - Gharib, Ahmed M.

AU - Wood, Bradford J.

AU - Levy, Elliot

AU - Sinkus, Ralph

AU - Virtaneva, Kimmo

AU - Sturdevant, Dan

AU - Martens, Craig

AU - Porcella, Stephen F.

AU - Goodman, Zachary D.

AU - Kanwar, Bittoo

AU - Myers, Robert P.

AU - Subramanian, Mani

AU - Hadigan, Colleen

AU - Masur, Henry

AU - Kleiner, David E.

AU - Heller, Theo

AU - Kottilil, Shyam

AU - Kovacs, Joseph A.

AU - Morse, Caryn G.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Drugs that reverse liver fibrosis are currently getting developed. Non-invasive quantification of the fibrosis degree is key to monitor therapy. This clinical trial for a novel drug was conducted at NIH. MR-Elastography was used as imaging biomarker to verify whether success of therapy can be monitored via biomechanics. MRE showed that the drug had no effect which was confirmed by histopathology. While for the drug company a deception, for MRE this was a success since it is more difficult to "see nothing when there is nothing". This paper convinced a major MRI constructor to translate our technology into a product.

AB - Drugs that reverse liver fibrosis are currently getting developed. Non-invasive quantification of the fibrosis degree is key to monitor therapy. This clinical trial for a novel drug was conducted at NIH. MR-Elastography was used as imaging biomarker to verify whether success of therapy can be monitored via biomechanics. MRE showed that the drug had no effect which was confirmed by histopathology. While for the drug company a deception, for MRE this was a success since it is more difficult to "see nothing when there is nothing". This paper convinced a major MRI constructor to translate our technology into a product.

KW - hepatic venous pressure gradient

KW - lysyl oxidases

KW - magnetic resonance elastography

KW - transforming growth factor beta-3

UR - http://www.scopus.com/inward/record.url?scp=84995807092&partnerID=8YFLogxK

U2 - 10.1111/liv.13177

DO - 10.1111/liv.13177

M3 - Article

C2 - 27232579

AN - SCOPUS:84995807092

SN - 1478-3223

VL - 36

SP - 1783

EP - 1792

JO - LIVER INTERNATIONAL

JF - LIVER INTERNATIONAL

IS - 12

ER -

Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this